Analysis of Antibodies to Newly Described Plasmodium falciparum Merozoite Antigens Supports MSPDBL2 as a Predicted Target of Naturally Acquired Immunity
暂无分享,去创建一个
D. Conway | K. Marsh | Marilyne Failly | G. Kamuyu | A. Salanti | K. Tetteh | F. Osier | L. Drought | C. Martin | Gathoni Kamuyu
[1] D. Kaslow,et al. Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities. , 2013, Vaccine.
[2] A. Cowman,et al. Modulation of PF10_0355 (MSPDBL2) Alters Plasmodium falciparum Response to Antimalarial Drugs , 2013, Antimicrobial Agents and Chemotherapy.
[3] Hong Zhou,et al. Overcoming Allelic Specificity by Immunization with Five Allelic Forms of Plasmodium falciparum Apical Membrane Antigen 1 , 2013, Infection and Immunity.
[4] Danny W. Wilson,et al. Defining the Antigenic Diversity of Plasmodium falciparum Apical Membrane Antigen 1 and the Requirements for a Multi-Allele Vaccine against Malaria , 2012, PloS one.
[5] D. Kwiatkowski,et al. Population Genomic Scan for Candidate Signatures of Balancing Selection to Guide Antigen Characterization in Malaria Parasites , 2012, PLoS genetics.
[6] Brian J. Smith,et al. Insights into Duffy Binding-like Domains through the Crystal Structure and Function of the Merozoite Surface Protein MSPDBL2 from Plasmodium falciparum* , 2012, The Journal of Biological Chemistry.
[7] Pardis C Sabeti,et al. Sequence-based association and selection scans identify drug resistance loci in the Plasmodium falciparum malaria parasite , 2012, Proceedings of the National Academy of Sciences.
[8] John C. Tan,et al. Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing , 2012, Nature.
[9] K. L. Le Roch,et al. Genomics and integrated systems biology in Plasmodium falciparum: a path to malaria control and eradication , 2012, Parasite immunology.
[10] J. Adams,et al. Design and Immunogenicity of a Novel Synthetic Antigen Based on the Ligand Domain of the Plasmodium vivax Duffy Binding Protein , 2011, Clinical and Vaccine Immunology.
[11] A. Thomas,et al. A Malaria Vaccine Based on the Polymorphic Block 2 Region of MSP-1 that Elicits a Broad Serotype-Spanning Immune Response , 2011, PloS one.
[12] D. Conway,et al. A polyvalent hybrid protein elicits antibodies against the diverse allelic types of block 2 in Plasmodium falciparum merozoite surface protein 1 , 2011, Vaccine.
[13] Dominic P. Kwiatkowski,et al. BASIGIN is a receptor essential for erythrocyte invasion by Plasmodium falciparum , 2011, Nature.
[14] Kazuhide Yahata,et al. PEXEL-independent trafficking of Plasmodium falciparum SURFIN4.2 to the parasite-infected red blood cell and Maurer's clefts. , 2011, Parasitology international.
[15] Daniel L. K. Yamins,et al. Identification and Functional Validation of the Novel Antimalarial Resistance Locus PF10_0355 in Plasmodium falciparum , 2011, PLoS genetics.
[16] Simon I. Hay,et al. Stable and Unstable Malaria Hotspots in Longitudinal Cohort Studies in Kenya , 2010, PLoS medicine.
[17] X. Su,et al. Recent Progress in Functional Genomic Research in Plasmodium falciparum , 2010, Current genomics.
[18] D. Conway,et al. Allele Frequency–Based and Polymorphism-Versus-Divergence Indices of Balancing Selection in a New Filtered Set of Polymorphic Genes in Plasmodium falciparum , 2010, Molecular biology and evolution.
[19] Rodrigo Lopez,et al. A new bioinformatics analysis tools framework at EMBL–EBI , 2010, Nucleic Acids Res..
[20] Jack S. Richards,et al. The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis , 2010, PLoS medicine.
[21] Christopher G. Adda,et al. Recombinant protein vaccines against the asexual blood-stages of Plasmodium falciparum , 2010, Human vaccines.
[22] A. Thomas,et al. Humoral Immune Response to Mixed PfAMA1 Alleles; Multivalent PfAMA1 Vaccines Induce Broad Specificity , 2009, PloS one.
[23] C. Blanc,et al. Toward the Rational Design of a Malaria Vaccine Construct Using the MSP3 Family as an Example: Contribution of Antigenicity Studies in Humans , 2009, Infection and Immunity.
[24] P. Druilhe,et al. Toward the Rational Design of a Malaria Vaccine Construct Using the MSP3 Family as an Example: Contribution of Immunogenicity Studies in Models , 2009, Infection and Immunity.
[25] Virander S. Chauhan,et al. A novel Plasmodium falciparum erythrocyte binding protein associated with the merozoite surface, PfDBLMSP. , 2009, International journal for parasitology.
[26] D. Conway,et al. Prospective Identification of Malaria Parasite Genes under Balancing Selection , 2009, PloS one.
[27] J. Barnwell,et al. A Conserved Multi-Gene Family Induces Cross-Reactive Antibodies Effective in Defense against Plasmodium falciparum , 2009, PloS one.
[28] D. Conway,et al. Breadth and Magnitude of Antibody Responses to Multiple Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Clinical Malaria , 2008, Infection and Immunity.
[29] Rodrigo Lopez,et al. Clustal W and Clustal X version 2.0 , 2007, Bioinform..
[30] Andrea Crisanti,et al. Profiling the antibody immune response against blood stage malaria vaccine candidates. , 2007, Clinical chemistry.
[31] D. Conway,et al. Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. , 2007, The Journal of infectious diseases.
[32] Ole Lund,et al. Epitope Mapping and Topographic Analysis of VAR2CSA DBL3X Involved in P. falciparum Placental Sequestration , 2006, PLoS pathogens.
[33] D. Conway,et al. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. , 2006, Vaccine.
[34] M. Wahlgren,et al. SURFIN is a polymorphic antigen expressed on Plasmodium falciparum merozoites and infected erythrocytes , 2005, The Journal of experimental medicine.
[35] R. Snow,et al. Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. , 2005, The Journal of infectious diseases.
[36] D. Conway,et al. Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. , 2004, Vaccine.
[37] Christopher J. Tonkin,et al. Localization of organellar proteins in Plasmodium falciparum using a novel set of transfection vectors and a new immunofluorescence fixation method. , 2004, Molecular and biochemical parasitology.
[38] Patricia De la Vega,et al. Discovery of Gene Function by Expression Profiling of the Malaria Parasite Life Cycle , 2003, Science.
[39] J. Derisi,et al. The Transcriptome of the Intraerythrocytic Developmental Cycle of Plasmodium falciparum , 2003, PLoS biology.
[40] D. Conway,et al. Repeat Sequences in Block 2 of Plasmodium falciparum Merozoite Surface Protein 1 Are Targets of Antibodies Associated with Protection from Malaria , 2003, Infection and Immunity.
[41] David L. Tabb,et al. A proteomic view of the Plasmodium falciparum life cycle , 2002, Nature.
[42] D. Conway,et al. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses , 2000, Nature Medicine.
[43] G. McVean,et al. Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome , 2007, Nature Genetics.
[44] W H TALIAFERRO,et al. Acquired immunity in malaria. , 1948, Abstracts. International Congress on Tropical Medicine and Malaria.